BVXV - InvestorNewsBreaks - BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) to Present at BIO CEO & Investor Conference
BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that its CEO Amir Reichman will present at the BIO CEO & Investor Conference. The event is slated to take place in New York from Feb. 6-9, 2023. Reichman’s presentation, scheduled to begin at 4:15 p.m. ET on Feb. 6, will focus on recent successful preclinical in vivo results of BiondVax’s innovative inhaled COVID-19 treatment. The presentation will also cover additional pipeline plans, including nanosized VHH-antibodies (“NanoAbs”) for the treatment of autoimmune diseases, such as psoriasis, asthma, psoriatic arthritis and macular degeneration. Reichman and Mark Germain, BiondVax’s chairman of the board, will be available to meet potential partners, collaborators and investors throughout the conference. Interested parties are encouraged to schedule one-on-one appointments as detailed in the announcement.
To view the full press release, visit https://ibn.fm/qSa5E
About BiondVax Pharmaceuticals Ltd.
BiondVax is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, BiondVax has executed eight clinical trials including a seven-country, 12,400-participant phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information, visit the company’s website at www.BiondVax.com.
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.